The series A financing will be used to establish a new cell and gene therapy hub in Boston, US.
Singapore-based Esco has eight established manufacturing and R&D hubs, with a focus on life science tools and technology, including for use vaccines and cell therapies. The new funding will be put towards a new innovation hub in Boston, US, and used for further expansion in China, which the company considers a priority market.
Commenting in a press release, Esco Chairman and CEO XQ Lin said: “This financing will enable the creation of an innovation hub in Boston, focused on cell and gene therapy tools and technologies. We will increase our R&D and in-licensing efforts to develop and commercialise novel life science research tools in emerging domains, thus enabling fundamental scientific discoveries and, ultimately, the diagnostics and medicines of tomorrow."